目的:原发性脊髓胶质母细胞瘤(PSCGBM)是一种罕见的恶性肿瘤,预后不良。迄今为止,没有建立这种罕见疾病的预后列线图.因此,我们的目的是建立一个列线图来预测PSCGBM的总生存期(OS)。
方法:回顾性收集苏州大学附属第二医院神经外科和监测流行病学和最终结果数据库中PSCGBM患者的临床资料。信息包括年龄,性别,种族,肿瘤扩展,切除范围,辅助治疗,婚姻状况,收入,记录诊断年份和从诊断到治疗的月份.单变量和多变量Cox回归分析用于确定PSCGBM的独立预后因素。构建了一个列线图来预测1年,1.5年,和PSCGBM的2年操作系统。
结果:共纳入132例患者。1年,1.5年,两年OS为45.5%,29.5%,18.9%,分别。四个变量:年龄组,肿瘤扩展,切除范围,和辅助治疗,被确定为独立的预后因素。列线图显示出具有C指数值的稳健判别,用于预测1年的OS,1.5年操作系统,和2年0.71(95%置信区间[CI],0.61-0.70),0.72(95%CI,0.62-0.70),和0.70(95%CI,0.61-0.70),分别。校准曲线在该队列中预测和观察到的生存概率之间显示出高一致性。
结论:我们首次开发并内部验证了预测PSCGBM生存结局的列线图。列线图有可能帮助临床医生对PSCGBM的生存结果进行个性化预测。
OBJECTIVE: Primary spinal cord glioblastoma (PSCGBM) is a rare malignancy with a poor prognosis. To date, no prognostic nomogram for this rare disease was established. Hence, we aimed to develop a nomogram to predict overall survival (OS) of PSCGBM.
METHODS: Clinical data of patients with PSCGBM was retrospectively collected from the neurosurgery department of Soochow University Affiliated Second Hospital and the Surveillance Epidemiology and End Results database. Information including age, sex, race, tumor extension, extent of resection, adjuvant treatment, marital status, income, year of diagnosis and months from diagnosis to treatment were recorded. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors for PSCGBM. A nomogram was constructed to predict 1-year, 1.5-year, and 2-year OS of PSCGBM.
RESULTS: A total of 132 patients were included. The 1-year, 1.5-year, and 2-year OS were 45.5%, 29.5%, and 18.9%, respectively. Four variables: age groups, tumor extension, extent of resection, and adjuvant therapy, were identified as independent prognostic factors. The nomogram showed robust discrimination with a C-index value for the prediction of 1-year OS, 1.5-year OS, and 2-year of 0.71 (95% confidence interval [CI], 0.61-0.70), 0.72 (95% CI, 0.62-0.70), and 0.70 (95% CI, 0.61-0.70), respectively. The calibration curves exhibited high consistencies between the predicted and observed survival probability in this cohort.
CONCLUSIONS: We have developed and internally validated a nomogram for predicting the survival outcome of PSCGBM for the first time. The nomogram has the potential to assist clinicians in making individualized predictions of survival outcome of PSCGBM.